Related Experiment Video

Updated: Apr 15, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

66

Targeting angiogenesis in lung cancer - Pitfalls in drug development

Wolfgang Hilbe1, Christian Manegold2, Andreas Pircher1

  • 1Department of Hematology and Oncology, Medical University Innsbruck, Austria ;

Translational Lung Cancer Research
|March 26, 2015
PubMed

Insights

Anti-angiogenic therapies show promise in non-small-cell lung cancer but face challenges. Future research needs to address clinical trial design, biomarkers, and disease complexity for better outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Anti-angiogenic therapies, including bevacizumab, are standard treatments for non-small-cell lung cancer.
  • Newer agents like tyrosine kinase inhibitors showed early promise but failed in later-stage trials.

Purpose of the Study:

  • To critically review the biology of tumor angiogenesis.
  • To identify potential pitfalls in anti-angiogenic drug development for lung cancer.

Main Methods:

  • Literature review and critical analysis of existing data.
  • Discussion of factors influencing clinical trial outcomes.

Main Results:

  • Phase II successes for novel anti-angiogenic drugs did not translate to Phase III efficacy.
  • Key challenges include clinical trial design, drug dosage, combination strategies, lack of biomarkers, and tumor angiogenesis complexity.

Conclusions:

  • Optimizing anti-angiogenic drug development requires addressing identified pitfalls.
  • Future trials should consider factors like cigarette smoke exposure and disease stage.
Keywords:
VEGFVEGFRanti-antiangiogenic therapybevacizumabtyrosine kinase inhibitor (TKI)

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
574